Comments |
Animals were sequentially immunized with recombinant gp120 (rgp120) from three different nonglycosylated isolates of HIV-1 (IIIB, SF2, and Z6). Spleen cells were fused with Sp2/0-Ag14 myeloma cells. 55-83 is one of a panel of antibodies developed by Dr. Suzanne Epstein that reacts with the gp120 of HIV-1. In ELISA the antibody reacts strongly with rgp120 IIIB and with gp120 MN (an isolate not used during immunization). It binds to the C1 region (positions 88 - 98) gp120 synthetic peptide used to map antibody reactivity. It is weakly cross-blocked by antibody 46-2 (see ATCC CRL-2186). The antibody blocks the binding of CD4 to rgp120 IIIB. |
References |
Reeves JP, et al. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Hybridoma 14: 235-242, 1995. PubMed: 7590785
Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.
Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.
Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.
|